Dyne Therapeutics heads into its August 10 earnings report with options traders at their most defensive in a year — while shorts quietly rebuild and a major insider cashes out nearly $18 million.
The clearest signal this week is in options. The put/call ratio jumped to 3.38, more than two and a half standard deviations above its 20-day average of 1.91 — the highest reading in the past 52 weeks. That is an extreme skew toward downside protection by any measure. The move is not a one-day spike: the ratio was 3.49 on Monday before settling slightly, having broken sharply higher from a range of 1.4–1.5 that persisted through most of June and early July. Options traders are paying a significant premium to hedge into the print.
Short interest adds to the cautious picture without being the dominant story on its own. Bears hold 16.1% of the free float short — a substantial position that has crept higher by roughly 1.5% over the past week and about 3% over the past month. The direction is persistent rather than explosive. Borrowing costs remain modest at 0.54%, and availability is loose at around 610% of shares already short, meaning there is no friction preventing new shorts from establishing or existing shorts from adding. The borrow market is wide open.
The insider angle deserves attention. Jason Rhodes — a board member, 10% owner, and venture capital affiliate — sold roughly 778,000 shares across July 6 and 7, generating close to $18 million in proceeds. The sales came at prices between $22.79 and $23.62, right around where the stock trades today. The 90-day net insider figure across all insiders actually shows net buying of around 1.9 million shares worth $40.7 million, suggesting this cluster of Rhodes sales runs against a broader backdrop of accumulation — though the recency and scale of his exits stands out.
The institutional picture offers some counterweight. T. Rowe Price disclosed a position of 20% of shares outstanding as of June 30, having added more than 13 million shares in the quarter. FMR added 2.3 million shares in the same period. That level of institutional conviction from long-only managers is notable for a pre-revenue biotech with a negative EV/EBITDA and a price-to-book of 8.4x. The mean analyst price target of $39.33 implies roughly 65% upside from current levels, with TD Cowen initiating at Buy in late June and Morgan Stanley maintaining Overweight despite trimming its target to $47 earlier this year. Bernstein holds a Market Perform at $24, essentially flat with the stock — the clearest expression of the bear case. The ORTEX short score of 67.1 has edged higher each day this week, now at a 10-day high.
The last three earnings prints have been sharp in both directions: down 8.7% and flat over five days in June, up 4.3% and then down 6.1% in May, and down 6.5% followed by a 13.3% five-day rally in March. The pattern suggests the stock moves hard on the day, often reverses, and the catalyst is binary. With the put/call ratio near its 52-week extreme and short interest at 16% of float still building, the August 10 print is the event worth watching — and whether the options hedging proves well-placed or gets unwound into a positive surprise will shape the next leg.
See the live data behind this article on ORTEX.
Open DYN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
